Evidence map›Paper›PMID 31875636›Full record

ArticleInternal medicine (Tokyo, Japan)2020

Secondary Pulmonary Alveolar Proteinosis Following Treatment with Azacitidine for Myelodysplastic Syndrome.

Miki Hashimoto, Hidehiro Itonaga, Yasuhito Nannya, Hirokazu Taniguchi, Yuichi Fukuda, Takafumi Furumoto, Machiko Fujioka, Sachie Kasai, Masataka Taguchi, Hiroaki Taniguchi and 10 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 6 institutions in 1 country.

Miki HashimotoDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Hidehiro ItonagaDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Yasuhito NannyaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan.
Hirokazu TaniguchiDepartment of Respiratory Medicine, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Yuichi FukudaDepartment of Respiratory Medicine, Sasebo City General Hospital, Japan.
Takafumi FurumotoDepartment of Hematology, Sasebo City General Hospital, Japan.
Machiko FujiokaDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Sachie KasaiDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Masataka TaguchiDepartment of Hematology, Nagasaki University Hospital, Japan.
Hiroaki TaniguchiDepartment of Hematology, Sasebo City General Hospital, Japan.
Shinya SatoDepartment of Hematology, Nagasaki University Hospital, Japan.
Yasushi SawayamaDepartment of Hematology, Nagasaki University Hospital, Japan.
Sunao AtogamiDepartment of Clinical Laboratory, Sasebo City General Hospital, Japan.
Keisuke IwasakiDepartment of Pathology, Sasebo City General Hospital, Japan.
Tomoko HataDepartment of Hematology, Atomic Bomb Disease and Hibakusha Medicine Unit, Atomic Bomb Disease Institute, Nagasaki University, Japan.
Hiroshi SodaDepartment of Respiratory Medicine, Sasebo City General Hospital, Japan.
Yukiyoshi MoriuchiDepartment of Hematology, Sasebo City General Hospital, Japan.
Koh NakataBioscience Medical Research Center, Niigata University Medical and Dental Hospital, Japan.
Seishi OgawaDepartment of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Japan.
Yasushi MiyazakiDepartment of Hematology, Nagasaki University Graduate School of Biomedical Sciences, Japan.
Sasebo City General Hospital · JPNagasaki University · JPNagasaki University Hospital · JPKyoto University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPNiigata University Medical and Dental Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Secondary pulmonary alveolar proteinosis (sPAP) is a complication of myelodysplastic syndrome (MDS). A 60-year-old woman was diagnosed with MDS with excess blasts-1. Fifty-four months after the initial diagnosis, treatment with azacitidine was initiated. Seventy-three months after the diagnosis, a bone marrow examination revealed increased myeloblasts, at which time computed tomography showed diffuse ground-glass opacities and interlobular septal thickening in the bilateral lower lung fields. A lung biopsy revealed the presence of PAP; therefore, the clinical diagnosis of MDS/sPAP was confirmed. Careful attention should be paid to the development of sPAP in MDS patients with pulmonary lesions during azacitidine treatment.

Indexed as

AzacitidineFemaleHumansMiddle AgedMyelodysplastic SyndromesPulmonary Alveolar ProteinosisTomography, X-Ray ComputedAzacitidineazacitidinemyelodysplastic syndromessecondary pulmonary alveolar proteinosisumbilical cord blood transplantation

Identifiers

PMID31875636
PMCPMC7205539
OpenAlexW2997426584

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.